In an analyst note, Larsen estimated the company had about 100,000 GLP-1-related members on its platform by the end of 2024, bringing in about $240 million in annualized revenue
Therefore, patients should inform their healthcare provider and laboratory personnel about their use of this medication
So, and do we know that as, of course all practitioners, we do intakes and look at health history, but when there's not enough research and you're having, you know, I don't think it's Right
And their potential to preserve and support muscle mass, when used alongside resistance training and adequate protein, challenges the narrative that they are tools of metabolic compromise rather than metabolic restoration
It is not FDA-approved for weight loss, but it can be a good treatment option for people with type 2 diabetes who are also interested in losing weight